Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Kwality Pharmaceuticals targets INR650-700 crores revenue in FY27 with EBITDA margins around 26-28%, aiming INR100 crores PAT.
From Kwality Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores.
- FY27: Expecting INR800-850 crores revenue with 28% EBITDA margin; oncology to rise to approx. INR150 crores.
- FY29 Target: INR1,000 crores revenue with 30% EBITDA margin; oncology expected to contribute INR300 crores (~30%).
- Registrations: 55 submissions made in Mexico (FY26), expecting all approved by end of 2027, with 25-30 more submissions planned in FY27.
- Biosimilars & Hormones: Anticipated INR200 crores revenue by FY29, viewed as incremental beyond INR1,000 crores target.
- Geography-wise Growth: Significant contributions from Germany (high-regulated market), Mexico, Colombia (LATAM), Algeria and MENA regions, GCC, Russia, and Southeast Asia.
2 more points from Kwality Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Kwality Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex planned for hormones, oncology expansion, biosimilars with clinical trials, R&D, and bioequivalence is around INR 260–270 crores.
- INR 46 crores of capex already done in FY26.
- Planned capex for FY27 is approximately INR 90 crores.
- Planned capex for FY28 is around INR 90–100 crores.
- Capex so far financed through existing working capital and re-utilization of bank loans without increasing borrowings.
2 more points from Kwality Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kwality Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- INR60-70 crores were stuck in payments for the last 1.5 to 2 quarters due to disruptions like the Strait of Hormuz situation.
- Out of the pending INR60 crores, around 40% (approx. INR25 crores) has already been realized.
- Complete realization of the pending amount is expected by June or July 2026.
- Debtor days have recently improved and come down to around 170 days and are expected to stabilize between 150-160 days.
2 more points from Kwality Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Kwality Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹157 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kwality Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Fermenta Biotech Ltd (Q4 FY26)
Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY . Key concall takeaways from Fermenta Biotech Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Amrutanjan Health Care Ltd (Q4 FY26)
149.77 Cr, up 10.60% YoY (Q4 FY25: Rs. Key concall takeaways from Amrutanjan Health Care Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Arthneeti Pro · Annual
Kwality Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kwality Pharmaceuticals Ltd Q4 FY26 results?
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Kwality Pharmaceuticals targets INR650-700 crores revenue in FY27 with EBITDA margins around 26-28%, aiming INR100 crores PAT.
What is Kwality Pharmaceuticals Ltd share price analysis?
Kwality Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.1 with a market cap of ₹2,655 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kwality Pharmaceuticals Ltd planning capital expenditure?
Total capex planned for hormones, oncology expansion, biosimilars with clinical trials, R&D, and bioequivalence is around INR 260–270 crores.
Keep Kwality Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.